The Second Hospital of Nanjing Medical University
87
24
26
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.1%
1 terminated/withdrawn out of 87 trials
92.3%
+5.8% vs industry average
10%
9 trials in Phase 3/4
8%
1 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (87)
Prevention of AIDS With Opportunistic Infection Paradoxical IRIS
Role: collaborator
Study of CMTS1215 Injection in Patients With Solid Tumors
Role: lead
Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections
Role: collaborator
CMTS0515-auWMT for Radiation Enteritis
Role: lead
CMTS4520 for Chronic Diarrhoea in Adults
Role: lead
Washed Microbiota Transplantation for Food Intolerance
Role: lead
Washed Microbiota Transplantation for Type 1 Diabetes Mellitus
Role: lead
Washed Microbiota Transplantation for Diabetic Gastroparesis
Role: lead
WMT for Autism Spectrum Disorder (ASD)
Role: lead
Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder
Role: lead
Washed Microbiota Transplantation for Malnutrition
Role: lead
Washed Microbiota Transplantation for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract
Role: lead
Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
Role: collaborator
CMTS4520 for Chronic Constipation in Adults
Role: lead
Fecal Microbiota Transplantation for Radiation Enteritis
Role: lead
Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications
Role: lead
CMTS0929 for Inflammatory Bowel Disease
Role: lead
CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults
Role: lead
CMTS0929 for Clostridioides Difficile Infection
Role: lead
Washed Microbiota Transplantation Combined with Enteral Nutrition for Gastroptosis
Role: lead